223 related articles for article (PubMed ID: 31686592)
1. Putative role of pharmacogenetics to elucidate the mechanism of tardive dyskinesia in schizophrenia.
Loonen AJ; Wilffert B; Ivanova SA
Pharmacogenomics; 2019 Nov; 20(17):1199-1223. PubMed ID: 31686592
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetics of tardive dyskinesia: an updated review of the literature.
Lanning RK; Zai CC; Müller DJ
Pharmacogenomics; 2016 Aug; 17(12):1339-51. PubMed ID: 27469238
[TBL] [Abstract][Full Text] [Related]
3. Striatal cholinergic interneurons and D2 receptor-expressing GABAergic medium spiny neurons regulate tardive dyskinesia.
Bordia T; Zhang D; Perez XA; Quik M
Exp Neurol; 2016 Dec; 286():32-39. PubMed ID: 27658674
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetics of tardive dyskinesia in schizophrenia: The role of
Boiko AS; Ivanova SA; Pozhidaev IV; Freidin MB; Osmanova DZ; Fedorenko OY; Semke AV; Bokhan NA; Wilffert B; Loonen AJM
World J Biol Psychiatry; 2020 Jan; 21(1):72-77. PubMed ID: 30623717
[No Abstract] [Full Text] [Related]
5. Schizophrenia-associated gene dysbindin-1 and tardive dyskinesia.
Maes MS; Lu JY; Tiwari AK; Freeman N; de Luca V; Müller DJ; Voineskos AN; Potkin SG; Lieberman JA; Meltzer HY; Remington G; Kennedy JL; Zai CC
Drug Dev Res; 2021 Aug; 82(5):678-684. PubMed ID: 32394511
[TBL] [Abstract][Full Text] [Related]
6. Analysis of genetic variations in the dopamine D1 receptor (DRD1) gene and antipsychotics-induced tardive dyskinesia in schizophrenia.
Lai IC; Mo GH; Chen ML; Wang YC; Chen JY; Liao DL; Bai YM; Lin CC; Chen TT; Liou YJ
Eur J Clin Pharmacol; 2011 Apr; 67(4):383-388. PubMed ID: 21181138
[TBL] [Abstract][Full Text] [Related]
7. Genetic underpinnings of tardive dyskinesia: passing the baton to pharmacogenetics.
Thelma B; Srivastava V; Tiwari AK
Pharmacogenomics; 2008 Sep; 9(9):1285-306. PubMed ID: 18781856
[TBL] [Abstract][Full Text] [Related]
8. Association study indicates a protective role of phosphatidylinositol-4-phosphate-5-kinase against tardive dyskinesia.
Fedorenko OY; Loonen AJ; Lang F; Toshchakova VA; Boyarko EG; Semke AV; Bokhan NA; Govorin NV; Aftanas LI; Ivanova SA
Int J Neuropsychopharmacol; 2014 Dec; 18(6):. PubMed ID: 25548108
[TBL] [Abstract][Full Text] [Related]
9. Oxidative stress and tardive dyskinesia: pharmacogenetic evidence.
Cho CH; Lee HJ
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Oct; 46():207-13. PubMed ID: 23123399
[TBL] [Abstract][Full Text] [Related]
10. Dopamine D3 receptor variant and tardive dyskinesia.
Rietschel M; Krauss H; Müller DJ; Schulze TG; Knapp M; Marwinski K; Maroldt AO; Paus S; Grünhage F; Propping P; Maier W; Held T; Nöthen MM
Eur Arch Psychiatry Clin Neurosci; 2000; 250(1):31-5. PubMed ID: 10738862
[TBL] [Abstract][Full Text] [Related]
11. Association of dopaminergic and serotonergic genes with tardive dyskinesia in patients with chronic schizophrenia.
Segman RH; Goltser T; Heresco-Levy U; Finkel B; Shalem R; Schlafman M; Yakir A; Greenberg D; Strous R; Lerner A; Shelevoy A; Lerer B
Pharmacogenomics J; 2003; 3(5):277-83. PubMed ID: 14583797
[TBL] [Abstract][Full Text] [Related]
12. Association analysis of polymorphisms in the N-methyl-D-aspartate (NMDA) receptor subunit 2B (GRIN2B) gene and tardive dyskinesia in schizophrenia.
Liou YJ; Wang YC; Chen JY; Bai YM; Lin CC; Liao DL; Chen TT; Chen ML; Mo GH; Lai IC
Psychiatry Res; 2007 Dec; 153(3):271-5. PubMed ID: 17669510
[TBL] [Abstract][Full Text] [Related]
13. Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia.
Segman RH; Heresco-Levy U; Finkel B; Goltser T; Shalem R; Schlafman M; Dorevitch A; Yakir A; Greenberg D; Lerner A; Lerer B
Mol Psychiatry; 2001 Mar; 6(2):225-9. PubMed ID: 11317227
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetics for off-patent antipsychotics: reframing the risk for tardive dyskinesia and access to essential medicines.
Ozdemir V; Aklillu E; Mee S; Bertilsson L; Albers LJ; Graham JE; Caligiuri M; Lohr JB; Reist C
Expert Opin Pharmacother; 2006 Feb; 7(2):119-33. PubMed ID: 16433578
[TBL] [Abstract][Full Text] [Related]
15. Association study between the neurexin-1 gene and tardive dyskinesia.
Lanning R; Lett TA; Tiwari AK; Brandl EJ; de Luca V; Voineskos AN; Potkin SG; Lieberman JA; Meltzer HY; Müller DJ; Remington G; Kennedy JL; Zai CC
Hum Psychopharmacol; 2017 Jan; 32(1):. PubMed ID: 28120489
[TBL] [Abstract][Full Text] [Related]
16. Pharmacotherapy for the treatment of tardive dyskinesia in schizophrenia patients.
Witter DP; Holbert RC; Suryadevara U
Expert Opin Pharmacother; 2017 Jul; 18(10):965-972. PubMed ID: 28443349
[TBL] [Abstract][Full Text] [Related]
17. Association study of Disrupted-In-Schizophrenia-1 gene variants and tardive dyskinesia.
Lu JY; Tiwari AK; Zai GC; Rastogi A; Shaikh SA; Müller DJ; Voineskos AN; Potkin SG; Lieberman JA; Meltzer HY; Remington G; Wong AHC; Kennedy JL; Zai CC
Neurosci Lett; 2018 Nov; 686():17-22. PubMed ID: 30118782
[TBL] [Abstract][Full Text] [Related]
18. Pathophysiology and drug therapy of tardive dyskinesia: current concepts and future perspectives.
Kulkarni SK; Naidu PS
Drugs Today (Barc); 2003 Jan; 39(1):19-49. PubMed ID: 12669107
[TBL] [Abstract][Full Text] [Related]
19. [Pharmacogenetic assessment of antipsychotic-induced tardive dyskinesia: contribution of 5-hydroxytryptamine 2C receptor gene and of a combination of dopamine D3 variant allele (Gly) and MnSOD wild allele (Val)].
Zhang Z; Hou G; Zhang X; Yao H; Sha W; Zhang X
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2003 Apr; 20(2):98-102. PubMed ID: 12673575
[TBL] [Abstract][Full Text] [Related]
20. Tardive dyskinesia: Who gets it and why.
Frei K
Parkinsonism Relat Disord; 2019 Feb; 59():151-154. PubMed ID: 30522959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
